Oxigene
Executive Summary
Former Aventis VP-Oncology David Chaplin, PhD, becomes chief operating officer and head of research & development at Oxigene. Prior to the merger with Hoechst Marion Roussel, Chaplin was senior director of oncology at Rhone-Poulenc Rorer